The kinetic changes induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) on hemopoietic cells were assessed in physiological conditions by administering GM-CSF (8 Ag/kg per d) for 3 d to nine patients with solid tumors and normal bone marrow (BM), before chemotherapy. GM-CSF increased the number of circulating granulocytes and monocytes; platelets, erythrocytes, lymphocyte number, and subsets were unmodified. GM-CSF increased the percentage of BM S phase BFU-E (from 32±7 to 79±16%), day 14 colony-forming unit granulocyte-macrophage (CFU-GM) (from 43±20 to 82±11%) and day 7 CFU-GM (from 41±14 to 56±20%). The percentage of BM myeloblasts, promyelocytes, and myelocytes in S phase increased from 26±14 to 41±6%, and that of erythroblasts increased from 25±12 to 30±12%. This suggests that GM-CSF activates both erythroid and granulomonopoietic progenitors but that, among the morphologically recognizable BM precursors, only the granulomonopoietic lineage is a direct target of the molecule. GM-CSF increased the birth rate of cycling cells from 1.3 to 3.4 cells %/h and decreased the duration of the S phase from 14.3 to 9.1 h and the cell cycle time from 86 to 26 h. After treatment discontinuation, the number of circulating granulocytes and monocytes rapidly fell. The proportion of S phase BM cells dropped to values lower than pretreatment levels, suggesting a period of relative refractoriness to cell cycle-active antineoplastic agents.
hemopoietic precursors, mature granulocytes, and monocytes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Alone or in combination with other hemopoietins, it stimulates the proliferation and differentiation of multipotent and lineage-committed erythroid (BFU-E), granulomonocytic (CFU-GM) and megakaryocytic progenitors (1-6).
Recent evidence also suggests an in vivo action ofGM-CSF both in nonhuman primates and in humans (11) (12) (13) (14) (15) . The treatment with GM-CSF has increased the number of circulating granulocytes and monocytes in patients with AIDS and myelodisplastic syndromes and has shortened the leukopenic period in patients undergoing autologous bone marrow transplantation (13) (14) (15) . An increase in the number of circulating progenitors and in the percentage of S phase bone marrow (BM) CFU-GM after GM-CSF administration has also been observed (16, 17) . GM-CSF effects on platelet and erythocyte production and on circulating lymphocytes are less defined. These uncertainties may simply reflect the difficulty of assessing the response of hemopoietic cells to GM-CSF in subjects with already damaged hemopoiesis and demonstrate the importance of thoroughly exploring its activity in physiological conditions. Determining which cells are the target ofthe molecule and how and to what extent their proliferation is influenced in vivo would allow proper planning of therapeutic trials with GM-CSF.
In this paper we have investigated the cellular composition and the kinetic features of peripheral blood (PB) and BM in nine patients with solid tumors and normal BM treated for 3 d with GM-CSF (8 Ag/kg per d) before chemotherapy.
We confirm that GM-CSF is in vivo a powerful stimulator of myelopoiesis and we add three new observations. First, GM-CSF delivers a striking proliferative signal to BM-committed progenitors CFU-GM and BFU-E, whereas its effect on morphologically identifiable precursors (amplification compartment) is predominantly restricted to the granulopoietic lineage. Second, GM-CSF shortens the cell cycle time (Ta) and the duration of S phase (Ta) of BM cycling cells and more than doubles their birth rate (Kb). Third, after discontinuation of GM-CSF, the BM-proliferative activity drops rapidly to values lower than pretreatment levels. These data may provide the basis for a more rational and kinetically interrelated administration of cell cycle-specific drugs and GM-CSF in cancer protocols.
Methods

Patients
Patients with histologically proven neoplasia not involving the myeloid system and normal BM participated in the study. Each patient gave written informed consent according to the Helsinki declaration. All but two patients had Hb levels > 12 g%. Two patients had lower levels of Hb Before and during the course of the study, the patients were monitored daily by the recording of vital signs, physical examination, determination ofthe complete blood count with differential (including neutrophil segmentation by the Arneth score), and reticulocyte counts.
A BM aspirate for morphological, immunological, kinetic, and in vitro culture studies was performed in all patients before and 3 d after starting the treatment. One or two additional BM aspirates were performed 1-4 d after discontinuing GM-CSF. At national, Buckinghamshire, UK; in duplicate). After 30 min incubation at 37°C the reaction was stopped by the addition of 5 ml ice-cold HBSS containing 0.5 mg/ml unlabeled thymidine. After three washes, the cells were resuspended in IMDM: CFU-GM and BFU-E cultures were prepared with standard procedure ( 19) , seeding 1 X I05 cells/dish of the original cell suspension. For CFU-GM, 10% conditioned medium of the 5637 cell line was the source of CSFs. BFU-E were prepared in presence of 1.5 IU erythropoietin (Toyobo, Osaka, Japan), 0.2 mM hemin and 10% human cord blood endothelium supernatant as source of burst-promoting activity (BPA).
After 7-and 14-d incubation periods, the number of colonies and bursts was evaluated by two independent investigators. The Eastman Kodak, Rochester, NY). After 2-3 d of exposure, the slides were developed with Kodak D19 developer and stained with buffered Giemsa (pH 7.2). Only slides with a mean background less than 2 (i.e., the number of grains in the mean area occupied by a nucleus) were considered. All cells with more than six grains over the nucleus were considered positive; however, > 90% of positive cells in our preparations had > 20 grains. The proportion of labelled cells was considered the labeling index (LI) of the population studied (21, 22) . 
Peripheral blood cells
The morphology of peripheral mature cells was studied on Giemsastained cells. The segmentation of neutrophils (Arneth score) was determined by calculating the mean number of lobes in 100 neutrophils. The fraction of CFU-GM in S phase was assessed as above starting from a cell preparation of 1 
Results
Peripheral blood changes induced by GM-CSF As shown in Table I , the absolute number of granulocytes and monocytes was increased three to fourfold during the treatment with GM-CSF. Platelets did not change and reticulocytes increased only marginally. The increase in granulocytes (both neutrophils and eosinophils) was accompanied by a marked shift to the left, as witnessed by the Arneth score. Moreover, sporadic myelocytes and metamyelocytes appeared in the PB, their number being higher shortly after discontinuation of treatment. Table II shows the absolute number of day 14 CFU-GM circulating in the PB at various times of the study and their proportion in S phase. Some increase in the absolute number of circulating progenitors (from 144±96 to 376±308 CFU-GM/ml) was evident at the end of treatment. This was observed in five of seven cases and marked patient to patient variations were evident. The percentage of S phase CFU-GM was only slightly increased by GM-CSF. Table IV shows the percentage of BM CFU-GM (day 14 CFU-GM and their more mature progeny day 7 CFU-GM) and BFU-E in S phase (as determined by the [3H]Tdr suicide technique) at various time intervals. GM-CSF induced a marked and significant increase in day 14 CFU-GM (from 43±20 to 82±11%) and BFU-E (from 32±7 to 79±10%) in S phase and to a lesser extent of day 7 CFU-GM (from 41 ± 14 to 56±20%).
(iii) KINETICS OF MORPHOLOGICALLY IDENTIFIABLE PRECURSORS (AMPLIFICATION COMPARTMENT)
(a) Kinetics in vitro. The proportion of low density cells (i.e., a population enriched in early myeloid cells) in S phase (as determined by BrdU incorporation) rose from 19±4 to 32±7% (Table IV) . The autoradiographic analysis allowed separate evaluation of the proliferation of early granulopoietic and early erythroid cells induced by GM-CSF. The overall percent- Average results±SD of the data obtained from eight patients. Plat, platelets. * P < 0.01 (compared with data at day 0); * P < 0.05. Effects ofGM-CSF discontinuation When treatment was discontinued, there was a rapid fall in the number of granulocytes and a slower decline of monocytes ( Table I ). The differentiation index, which had been decreased by the treatment, rapidly reached levels equal or even higher than the initial ones (Table III) .
The proportion of BM cycling cells rapidly decreased. 48-96 h after treatment, in the presence of a still hyperplastic BM (as inferred by the persistence of a decreased proportion of lymphocytes) the percentage of BrdU+ cells was lower than pretreatment values ( 13±5% at day 6) (Table IV) .
Autoradiographic analysis revealed that three days after GM-CSF discontinuation, the proportion of morphologically identifiable granulopoietic precursors in S phase dropped to 18±6%. Concomitantly, the proportion of progenitors in S phase dropped to values substantially lower than the initial ones (Table IV) .
Discussion
In this paper, we report the effects ofGM-CSF administered in vivo to subjects with normal bone marrow. The results can be divided into two parts. First, the modifications of PB and BM components and of their kinetics during GM-CSF treatment. Second, the analysis of the feedback phenomena that take place after discontinuing GM-CSF.
GM-CSF markedly stimulates the production of cells of the granulomonocytic pathway. Conceivably, the early rise of peripheral mature granulocytes and monocytes could depend on the release in the circulation of the marginal pool. However, our in vivo studies demonstrate that the BM production of immature granulopoietic cells is definitely an early and very active event after GM-CSF treatment. The pool of committed progenitors and morphologically identifiable granulopoietic precursors in S phase is significantly expanded and the leukoerythrogenetic ratio is markedly increased. GM-CSF is thus able to stimulate the proliferation of the entire granulopoietic Average results±SD of different experiments (n of samples are in parentheses). * P < 0.01 (compared with data at day 0); t P < 0.05. line because it acts both on committed progenitors and on the compartment of amplification precursors. The in vivo effect of GM-CSF on the erythroid compartment is different and shows an interesting discrepancy when compared with the effect on granulopoiesis. The percentage of BFU-E in the S phase is significantly increased, whereas the proportion of DNA-synthesizing erythroblasts changes only marginally and the absolute number of reticulocytes is basically unmodified. These in vivo data, in accordance with in vitro observations suggesting a BPA activity ofGM-CSF ( 1-6), indicate that GM-CSF acts predominantly on early erythroid progenitors and that the stimulation of BFU-E proliferation induced by GM-CSF is not sufficient per se to significantly enhance the production of erythrocytes. This implies that the proliferative effect exerted by GM-CSF on BFU-E can be brought to its final result only by the concomitant action of other hemopoietins. The most likely candidate to this role is erythropoietin, as witnessed by the data of Donahue et al. who observed a GM-CSF-induced reticulocytosis only in anemic primates with high erythropoietin levels (1 1).
The granulopoietic activity of GM-CSF is accomplished through important kinetic modifications that involve both committed progenitors and the morphologically identifiable cells that form the BM amplification compartment. First, progenitors are entering into cycle as a consequence of GM-CSF treatment. The second mechanism can account for the full realization of the reservoir capacity of BM morphologically identifiable precursors. The Kin plus the production ofcells into the compartment itselfcan be assumed to be equivalent to the K0u, even at time 0 (before administration of GM-CSF).
This argues against the possibility that a substantial proportion of cells might move out of cycle during the transit through this compartment. The absolute number of circulating CFU-GM increased in some patients during treatment (Table II) . This increase was variable and less evident than reported by Socinski et al. after higher doses of GM-CSF for longer periods (16) . The most relevant observation in PB as compared with BM is that the percentage of circulating progenitors in S phase was only marginally modified by GM-CSF treatment, suggesting that also in a stress situation, normal CFU-GM need the BM environment to actively proliferate.
The absolute number of lymphocytes and their precursors, as well as the distribution of circulating lymphocyte subsets, did not change during treatment. Also activation antigens were not observed on the surface of PB lymphocytes, whose proliferative activity was not increased. These observations seem to rule out a direct action ofGM-CSF on lymphocytes. The moderate lymphocytosis observed by Groopman et al. in AIDS patients treated with GM-CSF for a longer period (14 d) (13) might be ascribed to an indirect action of the molecule (i.e., monokine release).
A rapid fall to normal values in the number of neutrophils and eosinophils followed discontinuation of treatment. The slower decline in the number of monocytes probably reflects their longer half life. BM proliferation, too, dropped rapidly, and reached values somewhat lower than those observed before starting the treatment. Three explanations for this phenomenon are possible. First, inhibitory substances (i.e., acidic isoferritins, prostaglandins E, lactoferrin) (26) whose action is no longer counteracted by pharmacologic levels of GM-CSF might slow the proliferation of cells. Second, the endogenous production of GM-CSF (and perhaps of other hemopoietic growth factors interacting with GM-CSF) might drop to values lower than the initial ones. Third, GM-CSF receptors might be downregulated on target cells. Whatever the biological reason for this slowing of proliferative activity, it appears likely that the 48-96 h after discontinuing the treatment with GM-CSF represent a period of partial refractoriness of BM cells to the cytoreductive effect of cell cycle-specific chemotherapeutic agents. This observation, supported by data in monkeys (12) , suggests that a short treatment with GM-CSF followed by chemotherapy (and perhaps by additional GM-CSF administration after chemotherapy) might reduce the hemopoietic toxicity of antineoplastic treatments. However, the possibility has to be considered that GM-CSF, by stimulating proliferation and differentiation in the committed progenitor pool, might recruit more primitive progenitors into cycle to replenish the BFU-E and CFU-GM. If this happens, chemotherapy soon after GM-CSF treatment might interfere with the BM repopulation and lead to prolonged aplasia. Carefully controlled clinical trials are needed to address this issue and to evaluate the proper interplay between GM-CSF and cytotoxic drug administration.
